Reardon Andrew sold LGND
June 1, 2026 · Form 4 insider transaction
Reardon Andrew sold 200 shares of Ligand Pharmaceuticals Incorporated at $230.41 per share, a transaction worth $46.1K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 1 day after the transaction.
Direction
Disposed (sell-side)
Shares
200
Price
$230.41
Total value
$46.1K
InsiderReardon Andrew
Role—
SecurityCommon Stock
Transaction codeS: Open-market sale
Transaction dateJune 1, 2026
Filing dateJune 2, 2026
Shares owned after41,382
OwnershipDirect
10b5-1 planYes
AmendedNo
Footnotes
The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1.